89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
-
New drug aims to reverse liver scarring in MASH patients
Disease control Recruiting nowThis study tests a drug called pegozafermin in people with advanced liver scarring (cirrhosis) due to MASH, a fatty liver disease. About 762 adults will receive the drug or a placebo to see if it can reduce scarring and prevent liver-related complications. The goal is to slow or …
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated May 26, 2026 12:02 UTC
-
New drug aims to reverse liver damage in MASH patients
Disease control Recruiting nowThis study tests a medicine called pegozafermin in adults with MASH (a type of fatty liver disease) and moderate liver scarring (stage F2 or F3). The goal is to see if it can improve scarring or resolve liver inflammation without making the scarring worse. About 1,350 participant…
Phase: PHASE3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated May 26, 2026 12:00 UTC